Patient-Centric Strategies for Drug Re-innovation

Abstract

Drug repurposing, often achieved via the FDA’s 505(b) (2) pathway, is an increasingly popular approach in today’s pharmaceutical environment. Repurposing or “re-innovation” comprises a multitude of techniques, which have resulted in wide-ranging commercial success. This article explores the diverse strategies that have been taken to repurpose drugs, and distinguishes a unifying theme among the most commercially successful examples—the ability to address significant unmet needs. The examples listed in this paper relate to small molecules drugs and certainly not exhaustive, however provide some of the key strategies that have been successful using “re-innovation” pathway.